Document Detail


Two or four hour [¹⁸F]FMISO-PET in HNSCC. When is the contrast best?
MedLine Citation:
PMID:  21165537     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PATIENTS, METHODS: As part of a prospective trial, 23 patients with cancers of the head and neck underwent [¹⁸F]fluorodeoxyglucose (FDG) PET before and during curative radiochemotherapy. Additionally, FMISO-PET studies 2 h and 4 h p.i. were done before treatment and after a mean dose of 11Gy, 23 Gy and 57 Gy during RCT. After coregistration, a dedicated software was used to define the gross tumour volume (GTV) by FDG PET for the primary tumour. This volume was overlaid to the FMISO images and hypoxia within the GTV was determined. The contrast between hypoxia determined by MISO2 and by MISO4 was investigated and analysed with the Wilcoxon-matched-pairs test.
RESULTS: Mean SUVmax in tumours of all examinations was 2.2 (stdev: 0.4, min: 1.3, max: 3.4) after 2 h and 2.4 (stdev: 0.7, min: 1.1, max: 4.4) after 4 h. In the neck musculature the mean SUVmax was 1.5 at both time points and the mean SUVmean decreased from 1.2 after 2 h to 1.1 after 4 h, respectively. These effects resulted in significantly rising contrast ratios from MISO2 to MISO4. The differently defined contrasts revealed significantly higher values for examinations 4 h p.i. (p < 0.002).
CONCLUSION: Data acquisition of [¹⁸F]FMISO should be done 4 h p.i. to gather the optimal contrast, preferably allowing further analysis, e. g. hypoxic sub volume definition for therapy planning.
Authors:
N Abolmaali; R Haase; A Koch; D Zips; J Steinbach; M Baumann; J Kotzerke; K Zöphel
Related Documents :
15738037 - Posterior sacculation of the uterus in a patient presenting with flank pain at 29 weeks...
20452417 - Use of magnetic resonance imaging (mri) and micro-computed tomography (micro-ct) in the...
16049997 - Meconium peritonitis: prenatal diagnosis, postnatal management and outcome.
16012307 - Fast fetal magnetic resonance imaging.
14712127 - Comparison of axial high-resolution ct and thin-section multiplanar reformation (mpr) f...
25045047 - Hippocampal-parietal dysconnectivity and glutamate abnormalities in unmedicated patient...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-12-17
Journal Detail:
Title:  Nuklearmedizin. Nuclear medicine     Volume:  50     ISSN:  0029-5566     ISO Abbreviation:  Nuklearmedizin     Publication Date:  2011  
Date Detail:
Created Date:  2011-02-21     Completed Date:  2011-04-12     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  7609387     Medline TA:  Nuklearmedizin     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  22-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carcinoma, Small Cell / radionuclide imaging*
Female
Head and Neck Neoplasms / radionuclide imaging*
Humans
Image Enhancement / methods*
Male
Middle Aged
Misonidazole / administration & dosage,  analogs & derivatives*,  diagnostic use
Positron-Emission Tomography / methods*
Radiopharmaceuticals / administration & dosage,  diagnostic use
Reproducibility of Results
Sensitivity and Specificity
Time Factors
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 13551-89-8/fluoromisonidazole; 8FE7LTN8XE/Misonidazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  FDG PET/CT in cancer therapy monitoring. Computer-assisted analysis of baseline together with up to ...
Next Document:  Brain metastasis in lung cancer. Comparison of cerebral MRI and 18F-FDG-PET/CT for diagnosis in the ...